Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avenue TherapeuticsATXI 33 EV-to-FCF is 1.05 as of Aug. 02, 2026, which is 13% below its 10-year median of 1.20. GuruFocus rates ATXI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 349 Biotechnology companies, Avenue Therapeutics ranks better than 74.79% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Avenue Therapeutics's Enterprise Value is $-1.14 Mil.
Avenue Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.09 Mil. Therefore, Avenue Therapeutics's EV-to-FCF for today is 1.05.
The historical rank and industry rank for Avenue Therapeutics's EV-to-FCF or its related term are showing as below:
ATXI'
s EV-to-FCF Range Over the Past 10 Years
Min: 0.22 Med: 1.2 Max: 1.67
Current: 1.05
During the past 11 years, the highest EV-to-FCF of Avenue Therapeutics was 1.67. The lowest was 0.22. And the median was 1.20.
ATXI's EV-to-FCF is ranked better than 74.79% of 349
companies
in the Biotechnology industry
Industry Median: 14.07
vs ATXI: 1.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avenue Therapeutics's PE Ratio (TTM) for today is calculated as:
Avenue Therapeutics's share price for today is $0.3877.
Avenue Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.530.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Avenue Therapeutics EV-to-FCF Related Terms
Avenue Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Avenue Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avenue Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avenue Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Avenue Therapeutics's EV-to-FCF falls into.
Avenue Therapeutics's current Enterprise Value is $-1.14 Mil.
Avenue Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avenue Therapeutics (ATXI) has a EV-to-FCF of 1.05 as of Aug. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Avenue Therapeutics and its competitors. This is 13% below median its historical median of 1.20. Over the past decade, Avenue Therapeutics' EV-to-FCF has ranged from 0.22 to 1.67. According to the industry distribution chart, Avenue Therapeutics ranks #88 out of 349 companies in the Biotechnology industry, placing it in the top 25.2%.
Is Avenue Therapeutics' EV-to-FCF too high?
Avenue Therapeutics' current EV-to-FCF of 1.05 is 13% below median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 1.67. The Biotechnology industry median EV-to-FCF is 14.07. Avenue Therapeutics' value of 1.05 is 92.5% below this industry median. Based on the distribution chart, Avenue Therapeutics ranks #88 out of 349 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Avenue Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' EV-to-FCF compare to LYRA and ZVSA?
According to the Biotechnology industry distribution chart, Avenue Therapeutics ranks #88 out of 349 companies for EV-to-FCF. This puts Avenue Therapeutics in the upper half of its industry. The industry median EV-to-FCF is 14.07. Avenue Therapeutics' value of 1.05 is 92.5% below this benchmark. Historically, Avenue Therapeutics' own EV-to-FCF has ranged from 0.22 to 1.67 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 14.07, Avenue Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.07, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avenue Therapeutics's current EV-to-FCF of 1.05 is 92.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Avenue Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avenue Therapeutics's current EV-to-FCF is 1.05, which is 13% below median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current EV-to-FCF of 1.05. The current EV-to-FCF is 1.05, which is 13% below median its 10-year median of 1.20 and 92.5% below the Biotechnology industry median of 14.07. Avenue Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current EV-to-FCF is 1.05 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
33GF Score
Get the complete analysis for ATXI
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATXI has been successfully added to your 
